Antonino Oliveri

Antonino Oliveri

Auto-generated profile, based on publicly available information

Antonino Oliveri

Division of Gastroenterology and Hepatology, University of Michigan Health System, Ann Arbor, MI, USA - 48109; Department of Computational Medicine and Bioinformatics, University of Michigan Medical School, Ann Arbor, MI, USA - 48109

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 September 2023 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
YCYanhua Chen
Yanhua Chen
XDXiaomeng Du
Xiaomeng Du
AKAnnapurna Kuppa
Annapurna Kuppa
MFMary Feitosa
Mary Feitosa
LBLawrence F. Bielak
Lawrence F. Bielak
ESElizabeth K. Speliotes
Elizabeth K. Speliotes

10 January 2024 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
AOAntonino Oliveri
Antonino Oliveri
RRRyan J Rebernick
Ryan J Rebernick
AKAnnapurna Kuppa
Annapurna Kuppa
APAsmita Pant
Asmita Pant
YCYanhua Chen
Yanhua Chen
ESElizabeth K. Speliotes
Elizabeth K. Speliotes

4 April 2024 in Journal of Hepatology
Verified
Journal Article
Open access
VCVincent Chen
Vincent Chen
XDXiaomeng Du
Xiaomeng Du
AOAntonino Oliveri
Antonino Oliveri
YCYanhua Chen
Yanhua Chen
AKAnnapurna Kuppa
Annapurna Kuppa
ESElizabeth K. Speliotes
Elizabeth K. Speliotes
Steatotic liver disease (SLD), characterized by elevated liver fat content (LFC), is influenced by genetics and diet. However, whether diet has a differential effect based on genetic risk is not well-characterized. We aimed to determine how genetic factors interact with diet to affect SLD in a large national biobank. We included UK Biobank participants with dietary intake measured by 24-hour recall and genotyping. The primary predictors were dietary pattern, PNPLA3-rs738409-G, TM6SF2-rs58542926-T, a 16-variant hepatic steatosis polygenic risk score (PRS), and gene-environment interactions. The primary outcome was LFC, and secondary outcomes were iron-controlled T1 time (cT1, a measure of liver inflammation and fibrosis) and liver-related events/mortality. A total of 21,619 participants met inclusion criteria. In non-interaction models, Mediterranean diet and intake of fruit/vegetables/legumes and fish associated with lower LFC, while higher red/processed meat intake and all genetic predictors associated with higher LFC. In interaction models, all genetic predictors interacted with Mediterranean diet and fruit/vegetable/legume intake, while the steatosis PRS interacted with fish intake and the TM6SF2 genotype interacted with red/processed meat intake, to affect LFC. Dietary effects on LFC were up to 3.8-fold higher in PNPLA3-rs738409-GG vs. -CC individuals, and 1.4-3.0-fold higher in the top vs. bottom quartile of the steatosis PRS. Gene-diet interactions were stronger in participants with vs. without overweight. The steatosis PRS interacted with Mediterranean diet and fruit/vegetable/legume intake to affect cT1 and most dietary and genetic predictors associated with risk of liver-related events or mortality by age 70. Effects of diet on LFC and cT1 were markedly accentuated in patients at increased genetic risk for SLD, implying dietary interventions may be more impactful in these populations. Genetic variants and diet both influence risk of hepatic steatosis, inflammation/fibrosis, and hepatic decompensation; however, how gene-diet interactions influence these outcomes has previously not been comprehensively characterized. We investigated this topic in the community-based UK Biobank and found that genetic risk and dietary quality interacted to influence hepatic steatosis and inflammation/fibrosis on liver MRI, so that the effects of diet were greater in people at elevated genetic risk. These results are relevant for patients and medical providers because they show that genetic risk is not fixed (i.e. modifiable factors can mitigate or exacerbate this risk) and realistic dietary changes may result in meaningful improvement in liver steatosis and inflammation/fibrosis. As genotyping becomes more routinely used in clinical practice, patients identified to be at high baseline genetic risk may benefit even more from intensive dietary counseling than those at lower risk, though future prospective studies are required.

5 April 2022 in JHEP Reports
Verified
Journal Article
Open access
VCVincent Chen
Vincent Chen
DBDaniel A. Burkholder
Daniel A. Burkholder
IMIsabel J. Moran
Isabel J. Moran
JDJacob V. DiBattista
Jacob V. DiBattista
MMMatthew J. Miller
Matthew J. Miller
ESElizabeth K. Speliotes
Elizabeth K. Speliotes
Alpha-1 antitrypsin deficiency is caused by mutations in SERPINA1, most commonly homozygosity for the Pi∗Z variant, and can present as liver disease. While heterozygosity for Pi∗Z (Pi∗MZ) is linked to increased risk of cirrhosis, whether the Pi∗MZ genotype is associated with an increased rate of decompensation among patients who already have compensated cirrhosis is not known. This was a retrospective study of Michigan Genomics Initiative participants with baseline compensated cirrhosis. The primary predictors were Pi∗MZ or Pi∗MS genotype (vs. Pi∗MM). The primary outcomes were hepatic decompensation with ascites, hepatic encephalopathy, or variceal bleeding, or the combined endpoint of liver-related death or liver transplant, both modeled with Fine-Gray competing risk models. We included 576 patients with baseline compensated cirrhosis who had undergone genotyping, of whom 474 had Pi∗MM, 49 had Pi∗MZ, and 52 had Pi∗MS genotypes. Compared to Pi∗MM genotype, Pi∗MZ was associated with increased rates of hepatic decompensation (hazard ratio 1.81; 95% CI 1.22-2.69; p = 0.003) and liver transplant or liver-related death (hazard ratio 2.07; 95% CI 1.21-3.52; p = 0.078). These associations remained significant after adjustment for severity of underlying liver disease, and were robust across subgroup analyses based on etiology, sex, obesity, and diabetes status. Pi∗MS was not associated with decompensation or death/transplantation. The SERPINA1 Pi∗MZ genotype is associated with an increased rate of hepatic decompensation and decreased transplant-free survival among patients with baseline compensated cirrhosis. There is a mutation in the gene SERPINA1 called Pi∗MZ which increases risk of liver scarring (cirrhosis); however, it is not known what effect Pi∗MZ has if someone already has cirrhosis. In this study, we found that people who had cirrhosis and Pi∗MZ developed complications from cirrhosis faster than those who did not have the mutation.

19 September 2019 in PLOS ONE
Verified
Journal Article
Open access
PDF file
gentilini davidegentilini davide
gentilini davide
AOAntonino Oliveri
Antonino Oliveri
Teresa FaziaTeresa Fazia
Teresa Fazia
APAlessandro Pini
Alessandro Pini
SMSusan Marelli
Susan Marelli
ABAnna Maria Di Blasio
Anna Maria Di Blasio
The diagnosis of Marfan spectrum includes a large number of clinical criteria. Although the identification of pathogenic variants contributes to the diagnostic process, its value to the prediction of clinical outcomes is still limited. An important novelty of the present study is represented by the statistical approach adopted to investigate genotype-phenotype correlation. The analysis has been improved considering the extended genetic information obtained by Next Generation Sequencing (NGS) and combining the effects of both rare and common genetic variants in an inclusive model. To this aim a cohort of 181 patients were analyzed with a NGS panel including 11 genes associated with Marfan spectrum. The genotype-phenotype correlation was also investigated considering the possibility to predict presence of a pathological mutation in Marfan syndrome (MFS) main genes based only on the analysis of phenotypic traits. Results obtained indicate that information about clinical traits can be summarized in a new variable that resulted significantly associated with the probability to find a pathological mutation in MFS main genes. This is important since the choice of the genetic test is often influenced by the phenotypic characterization of patients. Moreover, both rare and common variants were found to significantly contribute to clinical spectrum and their combination allowed to increase the percentage of phenotype variability that could be explained based on genetic factors. Results highlight the opportunity to take advantage of the overall genetic information obtained by NGS data to have a better clinical classification of patients.

9 August 2023 in Journal of Hepatology
Verified
Journal Article
Closed access
KUKapil Upadhyay
Kapil Upadhyay
XDXiaomeng Du
Xiaomeng Du
YCYanhua Chen
Yanhua Chen
BBBrandon Buscher
Brandon Buscher
VCVincent Chen
Vincent Chen
GBGraham F. Brady
Graham F. Brady